Do analysts recommend BCDA or BOLD?

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher probable upside, research analysts plainly believe BioCardia is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or BOLD more profitable?

Boundless Bio's return on equity of -70.89% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% Boundless Bio N/A -70.89% -47.37%

Does the media favor BCDA or BOLD?

In the previous week, BioCardia had 1 more articles in the media than Boundless Bio. MarketBeat recorded 3 mentions for BioCardia and 2 mentions for Boundless Bio. BioCardia's average media sentiment score of 1.29 beat Boundless Bio's score of 0.94 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Boundless Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BCDA or EXOZ?

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCardia is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or EXOZ more profitable?

eXoZymes' return on equity of -292.15% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% eXoZymes N/A -292.15% -158.66%

Does the media favor BCDA or EXOZ?

In the previous week, BioCardia had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for BioCardia and 2 mentions for eXoZymes. BioCardia's average media sentiment score of 1.29 beat eXoZymes' score of 0.63 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BCDA or KVAC?

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,214.81%. Given BioCardia's higher possible upside, analysts plainly believe BioCardia is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, BCDA or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than BioCardia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia $60K 272.52 -$8.23M -$0.64 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is BCDA or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% Keen Vision Acquisition N/A N/A N/A

Is ELTX or BCDA more profitable?

BioCardia's return on equity of -569.36% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% BioCardia N/A -569.36% -183.15%

Do analysts recommend BCDA or ALPS?

BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% ALPS Group Inc Ordinary Share N/A N/A N/A

BioCardia (BCDA) Competitors

$1.08 -0.02 (-1.82%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.09 +0.01 (+0.83%)

As of 09/11/2026 04:51 PM Eastern

Compare

BCDA vs. BOLD, EXOZ, KVAC, ELTX, and ALPS

Should you buy BioCardia stock or one of its competitors? BioCardia's main competitors and comparable companies include Boundless Bio (BOLD), eXoZymes (EXOZ), Keen Vision Acquisition (KVAC), Elicio Therapeutics (ELTX), and ALPS Group Inc Ordinary Share (ALPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCardia compare to Boundless Bio?

BioCardia (NASDAQ:BCDA) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Boundless Bio's return on equity of -70.89% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Boundless Bio	N/A	-70.89%	-47.37%

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher probable upside, research analysts plainly believe BioCardia is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioCardia had 1 more articles in the media than Boundless Bio. MarketBeat recorded 3 mentions for BioCardia and 2 mentions for Boundless Bio. BioCardia's average media sentiment score of 1.29 beat Boundless Bio's score of 0.94 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Boundless Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCardia has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioCardia has higher revenue and earnings than Boundless Bio. BioCardia is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	272.52	-$8.23M	-$0.64	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

Summary

BioCardia beats Boundless Bio on 10 of the 14 factors compared between the two stocks.

How does BioCardia compare to eXoZymes?

BioCardia (NASDAQ:BCDA) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

BioCardia has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, meaning that its share price is 214% more volatile than the broader market.

20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioCardia has higher earnings, but lower revenue than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	272.52	-$8.23M	-$0.64	N/A
eXoZymes	$70K	874.97	-$9.16M	-$1.19	N/A

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCardia is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioCardia had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for BioCardia and 2 mentions for eXoZymes. BioCardia's average media sentiment score of 1.29 beat eXoZymes' score of 0.63 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes' return on equity of -292.15% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
eXoZymes	N/A	-292.15%	-158.66%

Summary

BioCardia beats eXoZymes on 9 of the 15 factors compared between the two stocks.

How does BioCardia compare to Keen Vision Acquisition?

BioCardia (NASDAQ:BCDA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, BioCardia had 3 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 3 mentions for BioCardia and 0 mentions for Keen Vision Acquisition. BioCardia's average media sentiment score of 1.29 beat Keen Vision Acquisition's score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Positive
Keen Vision Acquisition	Neutral

BioCardia has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

Keen Vision Acquisition's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Keen Vision Acquisition	N/A	N/A	N/A

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,214.81%. Given BioCardia's higher possible upside, analysts plainly believe BioCardia is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

20.6% of BioCardia shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Keen Vision Acquisition has lower revenue, but higher earnings than BioCardia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	272.52	-$8.23M	-$0.64	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

BioCardia beats Keen Vision Acquisition on 6 of the 10 factors compared between the two stocks.

How does BioCardia compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, BioCardia had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for BioCardia and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.80 beat BioCardia's score of 1.29 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Very Positive
BioCardia	Positive

Elicio Therapeutics currently has a consensus price target of $19.75, suggesting a potential upside of 863.41%. BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,214.81%. Given BioCardia's higher possible upside, analysts plainly believe BioCardia is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Elicio Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

BioCardia's return on equity of -569.36% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
BioCardia	N/A	-569.36%	-183.15%

BioCardia has higher revenue and earnings than Elicio Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
BioCardia	$60K	272.52	-$8.23M	-$0.64	N/A

Summary

Elicio Therapeutics beats BioCardia on 8 of the 14 factors compared between the two stocks.

How does BioCardia compare to ALPS Group Inc Ordinary Share?

BioCardia (NASDAQ:BCDA) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

ALPS Group Inc Ordinary Share has higher revenue and earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	272.52	-$8.23M	-$0.64	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.33	1.21

BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioCardia had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 3 mentions for BioCardia and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 1.89 beat BioCardia's score of 1.29 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Positive
ALPS Group Inc Ordinary Share	Very Positive

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioCardia has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

Summary

ALPS Group Inc Ordinary Share beats BioCardia on 8 of the 15 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.35M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-1.69	14.18	274.94	25.33
Price / Sales	272.52	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	13.50	15.12	10.33	6.21
Net Income	-$8.23M	-$22.86M	$3.50B	$358.54M
7 Day Performance	N/A	-4.34%	-3.32%	-2.35%
1 Month Performance	16.27%	0.54%	-0.53%	-3.23%
1 Year Performance	-49.53%	40.74%	23.51%	8.79%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	3.6465 of 5 stars	$1.08 -1.8%	$25.00 +2,214.8%	-49.5%	$16.35M	$60K	N/A	40	News Coverage Positive News
BOLD Boundless Bio	0.9569 of 5 stars	$2.86 -0.3%	N/A	+148.2%	$65.29M	N/A	N/A	64	Analyst Upgrade
EXOZ eXoZymes	0.6736 of 5 stars	$6.31 -7.9%	N/A	-46.8%	$63.58M	$70K	N/A	29	News Coverage High Trading Volume
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
ELTX Elicio Therapeutics	3.0882 of 5 stars	$2.35 -2.5%	$19.75 +740.4%	-82.3%	$63.34M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. BOLD, EXOZ, KVAC, ELTX, and ALPS

How does BioCardia compare to Boundless Bio?

Summary

How does BioCardia compare to eXoZymes?

Summary

How does BioCardia compare to Keen Vision Acquisition?

Summary

How does BioCardia compare to Elicio Therapeutics?

Summary

How does BioCardia compare to ALPS Group Inc Ordinary Share?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. BOLD, EXOZ, KVAC, ELTX, and ALPS

How does BioCardia compare to Boundless Bio?

Is BCDA or BOLD more profitable?

Do analysts recommend BCDA or BOLD?

Does the media favor BCDA or BOLD?

Which has more risk & volatility, BCDA or BOLD?

Do institutionals and insiders have more ownership in BCDA or BOLD?

Which has stronger earnings & valuation, BCDA or BOLD?

Summary

How does BioCardia compare to eXoZymes?

Which has more risk & volatility, BCDA or EXOZ?

Do institutionals & insiders believe in BCDA or EXOZ?

Which has better valuation and earnings, BCDA or EXOZ?

Do analysts rate BCDA or EXOZ?

Does the media favor BCDA or EXOZ?

Is BCDA or EXOZ more profitable?

Summary

How does BioCardia compare to Keen Vision Acquisition?

Does the media prefer BCDA or KVAC?

Which has more risk & volatility, BCDA or KVAC?

Is BCDA or KVAC more profitable?

Do analysts prefer BCDA or KVAC?

Do insiders and institutionals believe in BCDA or KVAC?

Which has higher valuation & earnings, BCDA or KVAC?

Summary

How does BioCardia compare to Elicio Therapeutics?

Does the media favor ELTX or BCDA?

Do analysts prefer ELTX or BCDA?

Do insiders & institutionals hold more shares of ELTX or BCDA?

Which has more risk and volatility, ELTX or BCDA?

Is ELTX or BCDA more profitable?

Which has stronger earnings & valuation, ELTX or BCDA?

Summary

How does BioCardia compare to ALPS Group Inc Ordinary Share?

Which has stronger valuation and earnings, BCDA or ALPS?

Do analysts recommend BCDA or ALPS?

Does the media prefer BCDA or ALPS?

Do insiders and institutionals hold more shares of BCDA or ALPS?

Which has more risk and volatility, BCDA or ALPS?

Is BCDA or ALPS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools